WEST PHARMACEUTICAL SERVICES INC (WST): Results of Operations and Financial Condition
WEST PHARMACEUTICAL SERVICES INC (WST) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exh991q22026earningsrelease.htm EX-99.1 Document Exhibit 99.1 West Reports Second-Quarter 2026 Results Raising Full-Year Net Sales and EPS guidance Exton, PA, July 23, 2026 – West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, high-quality
How this was made
The 30-second read
Why it matters
The newest actionable information is the raised full-year 2026 net sales and adjusted EPS guidance, supported by Q2 results (net sales, EPS, operating cash flow) and segment growth in HVP components and delivery devices.
Market read
Traders can update valuation and positioning based on the raised FY adjusted EPS range ($8.85 to $9.05) and FY net sales range ($3.345B to $3.380B) disclosed in the filing.
What to watch
The guidance includes an estimated FX benefit for FY net sales and excludes SmartDose 3.5mL from organic growth calculations going forward, which can complicate apples-to-apples comparisons.
Background
This is West Pharmaceutical’s SEC Form 8-K (Item 2.02) with an earnings release for Q2 2026, including updated full-year and third-quarter guidance.
Ticker impact
West Pharmaceutical reported Q2 2026 net sales of $872.3M and raised full-year net sales and adjusted EPS guidance ranges.
Likely positive bias for shares into the next trading session, with follow-through dependent on market reaction to the raised FY adjusted EPS range.
The filing is a primary earnings/guidance update (8-K with exhibit) including specific raised FY adjusted-diluted EPS guidance to $8.85 to $9.05 and FY net sales to $3.345B to $3.380B, alongside Q2 beats and operating cash flow/free cash flow.
Market effects
Strength in injectable components and delivery devices (HVP components, GLP-1 elastomers) may reinforce positive read-through for parts of the drug-device supply chain.
Limited direct regional spillover; primarily company-specific guidance for a US-listed manufacturer.
Global demand signals are implied via organic growth and biologics-related strength, but the filing is not a macro or regulatory catalyst.
Counterpoint
Organic growth strength could be partially offset by FX headwinds and the company’s reliance on specific end-markets like GLP-1 elastomers, which may face demand volatility.
Key entities
- companyWest Pharmaceutical Services, Inc.
NYSE-listed injectable solutions and services provider that raised FY 2026 guidance and declared a third-quarter dividend.
